Frank Karbe - 03 Jun 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Reporting relationship: Director
Issuer ticker: PHAT
Reported as of: 03 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2025, 16:58:25 UTC
Prior SEC filing: 26 Feb 2025
Next SEC filing: 12 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Steven Basta, Attorney-in-Fact for Frank Karbe

Key filing fact

Frank Karbe filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 05 Jun 2025.

Key facts

This page summarizes Frank Karbe's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2025, 16:58.

Change

Previous filing in this sequence was filed on 26 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001276700 Primary reporting owner

KARBE FRANK

Relationship: Director
Address: C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK
Signature: /s/ Steven Basta, Attorney-in-Fact for Frank Karbe
Signature date: 05 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHAT transaction

Common Stock

Award

Transaction value: $0
Shares: +10,500
Change %: +18%
Price: $0.000000
Shares after: 67,500
Date: 03 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PHAT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,500
Change %
Price: $0.000000
Shares after: 17,500
Date: 03 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $4.95
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Footnote F2

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.